{"id":33360,"date":"2020-08-12T17:38:11","date_gmt":"2020-08-12T16:38:11","guid":{"rendered":"https:\/\/www.biotechpharmasummit.com\/?page_id=33360"},"modified":"2021-03-18T12:30:06","modified_gmt":"2021-03-18T12:30:06","slug":"carla-leibowitz","status":"publish","type":"page","link":"https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2019-speakers\/carla-leibowitz\/","title":{"rendered":"Carla Leibowitz"},"content":{"rendered":"<div class=\"vgblk-rw-wrapper limit-wrapper\">\n<h2>Carla Leibowitz<\/h2>\n<h4>Global head of healthcare partnerships at NVIDIA<\/h4>\n\t<p>Carla Leibowitz is a growth and innovation executive currently leading Corporate Development Arterys, the first company to achieve FDA clearances for several products and a platform that combine cloud computing and artificial intelligence in the medical imaging space. In her role, Carla oversees corporate strategy and planning, business development, geographic expansion and investor relations.<\/p>\n<p>She has an MBA from the Stanford Graduate School of Business and engineering degrees from both MIT and Stanford. Prior to joining Arterys, Carla spent 3 years at Bain &amp; Company, consulting for top biotech, diagnostic and hospital clients. Before to that, Carla designed medical devices and led device development teams at several companies and has more than 16 patents under her name.<\/p>\n\t\t\t\t\t\t\t<img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Carla-Leibowitz_Arterys_BioTech_Pharma_summit_2.jpeg\" alt=\"Carla-Leibowitz_Arterys_BioTech_Pharma_summit_2\" itemprop=\"image\" height=\"1224\" width=\"820\" title=\"Carla-Leibowitz_Arterys_BioTech_Pharma_summit_2\" onerror=\"this.style.display='none'\" sizes=\"(max-width: 768px) 100vw, 100vw\" srcset=\"data:image\/svg+xml;utf8,<svg%20xmlns=&quot;http:\/\/www.w3.org\/2000\/svg&quot;%20viewBox=&quot;0%200%20820%201224&quot;%20height=&quot;1224px&quot;%20width=&quot;820px&quot;\/>&#8221; data-srcset=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Carla-Leibowitz_Arterys_BioTech_Pharma_summit_2.jpeg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Carla-Leibowitz_Arterys_BioTech_Pharma_summit_2-201&#215;300.jpeg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Carla-Leibowitz_Arterys_BioTech_Pharma_summit_2-686&#215;1024.jpeg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Carla-Leibowitz_Arterys_BioTech_Pharma_summit_2-768&#215;1146.jpeg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Carla-Leibowitz_Arterys_BioTech_Pharma_summit_2-630&#215;940.jpeg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Carla-Leibowitz_Arterys_BioTech_Pharma_summit_2-420&#215;627.jpeg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Carla-Leibowitz_Arterys_BioTech_Pharma_summit_2-315&#215;470.jpeg 315w&#8221;>\t\t\t\t\t\t\t\n<h3>\n\tTitle: Image-based CDx solutions\n\t<\/h3>\n\t<a href=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Cdx-Biomarkers-2019_Porto_Noehammer_2.pdf\" target=\"_blank\" role=\"button\" rel=\"noopener noreferrer\">\n\t\t\t\t\tPresentation not available\n\t<\/a>\n<h4>\n\t\t\t<a href=\"#\" title=\"On the Web\" target=\"_self\" rel=\"noopener noreferrer\">\n\tOn the Web\n\t\t\t<\/a>\n\t<\/h4>\n\t<p><a href=\"https:\/\/www.nvidia.com\/en-us\/industries\/healthcare-life-sciences\/\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.nvidia.com\/<\/a><\/p>\n<h4>\n\t\t\t<a href=\"#\" title=\"On LinkedIn\" target=\"_self\" rel=\"noopener noreferrer\">\n\tOn LinkedIn\n\t\t\t<\/a>\n\t<\/h4>\n\t<p><a href=\"https:\/\/www.linkedin.com\/in\/carla-leibowitz-b13551\/\" target=\"_blank\" rel=\"noopener noreferrer\">Visit Profile<\/a><\/p>\n<\/div><!-- .vgblk-rw-wrapper -->","protected":false},"excerpt":{"rendered":"<p>Carla Leibowitz Global head of healthcare partnerships at NVIDIA Carla Leibowitz is a growth and innovation executive currently leading Corporate Development Arterys, the first company to achieve FDA clearances for several products and a platform that combine cloud computing and artificial intelligence in the medical imaging space. In her role, Carla oversees corporate strategy and&#8230;<\/p>\n","protected":false},"author":1,"featured_media":33361,"parent":33267,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"inline_featured_image":false,"footnotes":""},"class_list":["post-33360","page","type-page","status-publish","has-post-thumbnail","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Carla Leibowitz &#8226; BioTech Pharma Summit<\/title>\n<meta name=\"description\" content=\"Carla Leibowitz is a growth and innovation executive currently leading Corporate Development Arterys, the first company to achieve FDA clearances\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2019-speakers\/carla-leibowitz\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Carla Leibowitz &#8226; BioTech Pharma Summit\" \/>\n<meta property=\"og:description\" content=\"Carla Leibowitz is a growth and innovation executive currently leading Corporate Development Arterys, the first company to achieve FDA clearances\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2019-speakers\/carla-leibowitz\/\" \/>\n<meta property=\"og:site_name\" content=\"BioTech Pharma Summit\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/biotechpharmasummit\/\" \/>\n<meta property=\"article:modified_time\" content=\"2021-03-18T12:30:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Carla-Leibowitz_Arterys_BioTech_Pharma_summit.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"900\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@biotechsummit\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2019-speakers\/carla-leibowitz\/\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2019-speakers\/carla-leibowitz\/\",\"name\":\"Carla Leibowitz &#8226; BioTech Pharma Summit\",\"isPartOf\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2019-speakers\/carla-leibowitz\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2019-speakers\/carla-leibowitz\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Carla-Leibowitz_Arterys_BioTech_Pharma_summit.jpeg\",\"datePublished\":\"2020-08-12T16:38:11+00:00\",\"dateModified\":\"2021-03-18T12:30:06+00:00\",\"description\":\"Carla Leibowitz is a growth and innovation executive currently leading Corporate Development Arterys, the first company to achieve FDA clearances\",\"breadcrumb\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2019-speakers\/carla-leibowitz\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2019-speakers\/carla-leibowitz\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2019-speakers\/carla-leibowitz\/#primaryimage\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Carla-Leibowitz_Arterys_BioTech_Pharma_summit.jpeg\",\"contentUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Carla-Leibowitz_Arterys_BioTech_Pharma_summit.jpeg\",\"width\":900,\"height\":900},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2019-speakers\/carla-leibowitz\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.biotechpharmasummit.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Companion Diagnostics &#038; Biomarkers 2019 Speakers\",\"item\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2019-speakers\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Carla Leibowitz\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#website\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/\",\"name\":\"BioTech Pharma Summit\",\"description\":\"The Tomorrow&#039;s healthcare congress\",\"publisher\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.biotechpharmasummit.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#organization\",\"name\":\"EPM Group\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png\",\"contentUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png\",\"width\":2000,\"height\":2000,\"caption\":\"EPM Group\"},\"image\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/biotechpharmasummit\/\",\"https:\/\/x.com\/biotechsummit\",\"https:\/\/www.instagram.com\/biotechpharmasummit\/\",\"https:\/\/www.linkedin.com\/company\/biotech-pharma-summit\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Carla Leibowitz &#8226; BioTech Pharma Summit","description":"Carla Leibowitz is a growth and innovation executive currently leading Corporate Development Arterys, the first company to achieve FDA clearances","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2019-speakers\/carla-leibowitz\/","og_locale":"en_US","og_type":"article","og_title":"Carla Leibowitz &#8226; BioTech Pharma Summit","og_description":"Carla Leibowitz is a growth and innovation executive currently leading Corporate Development Arterys, the first company to achieve FDA clearances","og_url":"https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2019-speakers\/carla-leibowitz\/","og_site_name":"BioTech Pharma Summit","article_publisher":"https:\/\/www.facebook.com\/biotechpharmasummit\/","article_modified_time":"2021-03-18T12:30:06+00:00","og_image":[{"width":900,"height":900,"url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Carla-Leibowitz_Arterys_BioTech_Pharma_summit.jpeg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@biotechsummit","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2019-speakers\/carla-leibowitz\/","url":"https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2019-speakers\/carla-leibowitz\/","name":"Carla Leibowitz &#8226; BioTech Pharma Summit","isPartOf":{"@id":"https:\/\/www.biotechpharmasummit.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2019-speakers\/carla-leibowitz\/#primaryimage"},"image":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2019-speakers\/carla-leibowitz\/#primaryimage"},"thumbnailUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Carla-Leibowitz_Arterys_BioTech_Pharma_summit.jpeg","datePublished":"2020-08-12T16:38:11+00:00","dateModified":"2021-03-18T12:30:06+00:00","description":"Carla Leibowitz is a growth and innovation executive currently leading Corporate Development Arterys, the first company to achieve FDA clearances","breadcrumb":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2019-speakers\/carla-leibowitz\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2019-speakers\/carla-leibowitz\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2019-speakers\/carla-leibowitz\/#primaryimage","url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Carla-Leibowitz_Arterys_BioTech_Pharma_summit.jpeg","contentUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Carla-Leibowitz_Arterys_BioTech_Pharma_summit.jpeg","width":900,"height":900},{"@type":"BreadcrumbList","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2019-speakers\/carla-leibowitz\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.biotechpharmasummit.com\/"},{"@type":"ListItem","position":2,"name":"Companion Diagnostics &#038; Biomarkers 2019 Speakers","item":"https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2019-speakers\/"},{"@type":"ListItem","position":3,"name":"Carla Leibowitz"}]},{"@type":"WebSite","@id":"https:\/\/www.biotechpharmasummit.com\/#website","url":"https:\/\/www.biotechpharmasummit.com\/","name":"BioTech Pharma Summit","description":"The Tomorrow&#039;s healthcare congress","publisher":{"@id":"https:\/\/www.biotechpharmasummit.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.biotechpharmasummit.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.biotechpharmasummit.com\/#organization","name":"EPM Group","url":"https:\/\/www.biotechpharmasummit.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png","contentUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png","width":2000,"height":2000,"caption":"EPM Group"},"image":{"@id":"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/biotechpharmasummit\/","https:\/\/x.com\/biotechsummit","https:\/\/www.instagram.com\/biotechpharmasummit\/","https:\/\/www.linkedin.com\/company\/biotech-pharma-summit\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/33360","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/comments?post=33360"}],"version-history":[{"count":4,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/33360\/revisions"}],"predecessor-version":[{"id":36076,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/33360\/revisions\/36076"}],"up":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/33267"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/media\/33361"}],"wp:attachment":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/media?parent=33360"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}